Hsieh Chung-Bao, Chang Hao-Ming, Chen Teng-Wei, Chen Chung-Jueng, Chan De-Chuan, Yu Jyh-Cherng, Liu Yao-Chi, Chang Tzu-Ming, Shen Kuo-Liang
Division of General Surgery, Department of Surgery, National Defense Medical Center, Tri-Service General Hospital, 325 Sec 2 Cheng-Kung Road, Taipei, Taiwan, China.
World J Gastroenterol. 2004 Feb 15;10(4):505-8. doi: 10.3748/wjg.v10.i4.505.
To compare the therapeutic effect of transcatheter arterial chemoembolization (TACE), laparoscopic radiofrequency ablation (LRFA), and conservative treatment for the therapy of decompensated liver cirrhosis patients with hepatocellular carcinomas (HCC).
Between October 2000 and July 2003, one hundred patients with histologically proven primary HCC and clinical decompensated liver cirrhosis (Child classification B or C) were included in this study. Forty patients received LRFA (LRFA group), twenty received TACE (TACE group), and forty received conservative treatment (control group). We compared the survival, recurrence, and complication rates in these three groups, making adjustment using the tumor metastatic node staging system.
The major complication rate in the TACE group (9/20) was significantly higher than that in the LRFA group (7/40). For patients with TMN stage II HCC, the survival rate of the LRFA group was better than that of the TACE and control groups (P=0.003) but the recurrence rates between the LRFA and TACE groups did not differ.
The LRFA group of patients had better clinical outcomes in terms of survival and complication rates in comparison with the TACE group or conservative treatment in patients with decompensated liver cirrhosis, especially in TMN patients with stage II HCC. LRFA is thus an appropriate alternative treatment for poor liver function among patients with HCC.
比较经导管动脉化疗栓塞术(TACE)、腹腔镜射频消融术(LRFA)及保守治疗对失代偿期肝硬化合并肝细胞癌(HCC)患者的治疗效果。
2000年10月至2003年7月,本研究纳入100例经组织学证实为原发性HCC且临床诊断为失代偿期肝硬化(Child分级为B级或C级)的患者。40例患者接受LRFA治疗(LRFA组),20例接受TACE治疗(TACE组),40例接受保守治疗(对照组)。我们比较了三组患者的生存率、复发率及并发症发生率,并采用肿瘤转移淋巴结分期系统进行校正。
TACE组的主要并发症发生率(9/20)显著高于LRFA组(7/40)。对于TMN分期为II期的HCC患者,LRFA组的生存率优于TACE组和对照组(P = 0.003),但LRFA组和TACE组之间的复发率无差异。
与TACE组或保守治疗相比,LRFA组患者在失代偿期肝硬化患者,尤其是TMN分期为II期的HCC患者的生存率和并发症发生率方面具有更好的临床结局。因此,LRFA是HCC患者肝功能较差时的一种合适替代治疗方法。